

Leucine Rich Repeat Serine Treatment Pipeline Review H2 2016

Leucine Rich Repeat Serine Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, September 13, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the [Leucine Rich Repeat Serine](#)/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Complete Report@

<https://www.wiseguyreports.com/reports/636734-leucine-rich-repeat-serine-review-h2-2016>



Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-

registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/636734-leucine-rich-repeat-serine-review-h2-2016>

Table of Content

Product Description	30
Mechanism Of Action	30
R&D Progress	30
GNE-7915 - Drug Profile	31
Product Description	31
Mechanism Of Action	31
R&D Progress	31
ODS-2005294 - Drug Profile	32
Product Description	32
Mechanism Of Action	32
R&D Progress	32
ORS-1104 - Drug Profile	33
Product Description	33
Mechanism Of Action	33
R&D Progress	33
PF-06447475 - Drug Profile	34

Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Inhibit LRRK2 for Parkinson's Disease - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile 36
Product Description 36

Have any query@ <https://www.wiseguyreports.com/enquiry/636734-leucine-rich-repeat-serine-review-h2-2016>

Mechanism Of Action 36
R&D Progress 36
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
SR-9444 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TTT-3002 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) -

Dormant Projects 47

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) -

Featured News & Press Releases 48

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=636734
Continued...

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

[wiseguyreports](http://www.wiseguyreports.com)

+1 646 845 9349 / +44 208 133 9349

[email us here](mailto:sales@wiseguyreports.com)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.